This site uses cookies. These cookies collect information about how visitors use a website, for instance which pages visitors go to most often, and if they get error messages from web pages. These cookies don’t collect information that identifies a visitor. All information these cookies collect is used only to improve the website. By visiting this website, you agree that we can place these types of cookies on your device.

COMPANY HISTORY

1995 Exact Sciences is founded
2001 Exact Sciences holds Initial Public Offering
2004 Oncotype DX Breast Recurrence Score® test launched
2007 Oncotype DX Breast Recurrence Score test included in the American Society of Clinical Oncology (ASCO® ) guidelines
2008 Oncotype DX Breast Recurrence Score test included in the U.S. National Comprehensive Cancer Network (NCCN®) guidelines
2009 Oncotype DX Breast Recurrence Score test helps more than 100,000 patients worldwide
2010 Oncotype DX Colon Recurrence Score™ test launched
2011

Oncotype DX Breast DCIS Score™ test (ductal carcinoma in situ) launched

Oncotype DX Breast Recurrence Score test recognised by St. Gallen expert consensus

2013

Oncotype DX Genomic Prostate Score™ test launched

Oncotype DX Breast Recurrence Score test recommended by the National Institute for Health and Care Excellence (NICE)* in England

Oncotype DX breast cancer test included in the European Society for Medical Oncology (ESMO®) guidelines

2014

The Oncotype DX® portfolio of tests helps more than 500,000 patients worldwide

Cologuard®, the company's multi-target stool DNA, non-invasive colorectal cancer screening test approved by the U.S. Food and Drug Administration (FDA)

The American Cancer Society (ACS®) guidelines include Cologuard in a recommended list of screening options for colorectal cancer

2015

NHS patients in England gain access to the Oncotype DX Breast Recurrence Score test

2016

Updated NICE quality standard recommends the Oncotype DX test in early-stage breast cancer

2018

Landmark TAILORx primary results published in The New England Journal of Medicine, showing that the Oncotype DX Breast Recurrence Score test identifies the vast majority of women with node-negative disease who receive no substantial benefit from chemotherapy (approximately 80%), as well as the important minority for whom chemotherapy can be life-saving.

NICE expands recommendation for the Oncotype DX test to more patients with early-stage breast cancer

2019

Exact Sciences and Genomic Health combine, creating leading global cancer diagnostics company

The Oncotype DX portfolio of tests helps more than one million patients worldwide

2020

Exact Sciences completes acquisition of Paradigm and Viomics, extending leadership in advanced cancer diagnostics

*NICE © Diagnostics Guidance DG34, December 2018. www.nice.org.uk/guidance/dg34 (assessed Oct 2020). All rights reserved. Subject to Notice of rights NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication

You are now leaving this site.

Any third-party link you select from this site may take you to an Exact Sciences website intended for US audiences or a website that is not affiliated with Exact Sciences.